<--- Back to Details
First PageDocument Content
Rare diseases / Alexion Pharmaceuticals / Eculizumab / Paroxysmal nocturnal hemoglobinuria / Hemolytic-uremic syndrome / Myasthenia gravis / Hypophosphatasia / Nephrology / Health / Medicine / Acquired hemolytic anemia
Rare diseases
Alexion Pharmaceuticals
Eculizumab
Paroxysmal nocturnal hemoglobinuria
Hemolytic-uremic syndrome
Myasthenia gravis
Hypophosphatasia
Nephrology
Health
Medicine
Acquired hemolytic anemia

Add to Reading List

Source URL: files.shareholder.com

Download Document from Source Website

File Size: 1,14 MB

Share Document on Facebook

Similar Documents

Bone Marrow Transplantation, 523–527 & 2008 Macmillan Publishers Limited All rights reserved $32.00 www.nature.com/bmt  ORIGINAL ARTICLE

Bone Marrow Transplantation, 523–527 & 2008 Macmillan Publishers Limited All rights reserved $32.00 www.nature.com/bmt ORIGINAL ARTICLE

DocID: 1pSIX - View Document

Alexion to Acquire Synageva to Strengthen Global Leadership in Developing and Commercializing Transformative Therapies for Patients with Devastating and Rare Diseases -- Expands  Alexion’s  metabolic  franchise  wi

Alexion to Acquire Synageva to Strengthen Global Leadership in Developing and Commercializing Transformative Therapies for Patients with Devastating and Rare Diseases -- Expands  Alexion’s  metabolic  franchise  wi

DocID: 19nD4 - View Document

Clinical Flow Cytometry Symposium 2014 Date: Time: Venue:  Saturday, 7th June 2014

Clinical Flow Cytometry Symposium 2014 Date: Time: Venue: Saturday, 7th June 2014

DocID: 12RVP - View Document

NBT-RFV17092B Dr. Rother’s Figure 1 in PPT format_Rother1 25.ppt [Read-Only]

NBT-RFV17092B Dr. Rother’s Figure 1 in PPT format_Rother1 25.ppt [Read-Only]

DocID: QV4w - View Document

MEDICAL ASSISTANCE HANDBOOK  PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES 1.	 Requirements for Prior Authorization of Soliris (eculizumab) A.

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES 1. Requirements for Prior Authorization of Soliris (eculizumab) A.

DocID: LLi8 - View Document